trending Market Intelligence /marketintelligence/en/news-insights/trending/Kd1k_9REe-m-fGImYetyUA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Apricus Biosciences' erectile dysfunction drug approved in Mexico

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Apricus Biosciences' erectile dysfunction drug approved in Mexico

Apricus Biosciences Inc.'s erectile dysfunction drug Vitaros was approved for sale in Mexico.

Ferring Pharmaceuticals will market the drug on Apricus' behalf and paid the company $4.5 million in up-front payment as well as another $1.6 million in a regulatory milestone payment.

Apricus is eligible to receive up to a further $28 million in regulatory, launch and sales milestones, plus royalties on future net sales.

Vitaros is approved for use in more than 20 countries, including in parts of Europe.